Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects with Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging
Serra, M.; Bohnert, K.; Narda, M.; Granger, C.; Sadick, N.
Journal of Drugs in Dermatology Jdd 17(12): 1310-1315
2018
ISSN/ISBN: 1545-9616 PMID: 30586263 Document Number: 17668
Objective: To evaluate the safety and efficacy of ISDINCEUTICS Melaclear® serum (Barcelona, Spain) on skin brightness, skin quality, and signs of facial aging.
Document emailed within 1 workday
Related Documents
Ramírez, S.P.; Carvajal, A.C.; Salazar, J.C.; Arroyave, G.; Flórez, A.M.; Echeverry, H.F. 2013: Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma Journal of Drugs in Dermatology: Jdd 12(6): E106-E110Vanaman Wilson, M.J.; Jones, I.T.; Bolton, J.; Larsen, L.; Wu, D.C.; Goldman, M.P. 2017: A Randomized, Investigator-Blinded Comparison of two Topical Regimens in Fitzpatrick Skin Types III-Vi with Moderate to Severe Facial Hyperpigmentation Journal of Drugs in Dermatology: Jdd 16(11): 1127-1132
Hantash, B.M.; Jimenez, F. 2012: Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system Journal of Drugs in Dermatology: Jdd 11(5): 660-662
Fabi, S.; Massaki, N.; Goldman, M.P. 2012: Efficacy and tolerability of two commercial hyperpigmentation kits in the treatment of facial hyperpigmentation and photo-aging Journal of Drugs in Dermatology: Jdd 11(8): 964-968
Kircik, L.H.; Dahl, A.; Yatskayer, M.; Raab, S.; Oresajo, C. 2012: Safety and efficacy of two anti-acne/anti-aging treatments in subjects with photodamaged skin and mild to moderate acne vulgaris Journal of Drugs in Dermatology: Jdd 11(6): 737-740
Toossi, P.; Farshchian, M.; Malekzad, F.; Mohtasham, N.; Kimyai-Asadi, A. 2008: Subantimicrobial-dose doxycycline in the treatment of moderate facial acne Journal of Drugs in Dermatology: Jdd 7(12): 1149-1152
Roberts, W.E. 2015: Pollution as a risk factor for the development of melasma and other skin disorders of facial hyperpigmentation ‑ is there a case to be made? Journal of Drugs in Dermatology: Jdd 14(4): 337-341
Kircik, L.H. 2009: Tretinoin microsphere gel pump 0.04% versus tazarotene cream 0.05% in the treatment of mild-to-moderate facial acne vulgaris Journal of Drugs in Dermatology: Jdd 8(7): 650-654
Tanghetti, E.; Dhawan, S.; Green, L.; Del Rosso, J.; Draelos, Z.; Leyden, J.; Shalita, A.; Glaser, D.A.; Grimes, P.; Webster, G.; Barnett, P.; Le Gall, N. 2010: Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris Journal of Drugs in Dermatology: Jdd 9(5): 549-558
Dahl, A.; Yatskayer, M.; Raab, S.; Oresajo, C. 2013: Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone Journal of Drugs in Dermatology: Jdd 12(1): 52-58
E Silva, L.ís.P.C.T.; Luís, F.; Cabrera, H. 2008: Facial hyperpigmentation. amiodarone-induced hyperpigmentation American Family Physician 78(11): 1297-1298
Leyden, J.J.; Bruce, S.; Lee, C.S.; Ling, M.; Sheth, P.B.; Stewart, D.M.; Werschler, W.P.; Gilbert, R.D.; Kircik, L. 2013: A randomized, phase 2, dose-ranging study in the treatment of moderate to severe inflammatory facial acne vulgaris with doxycycline calcium Journal of Drugs in Dermatology: Jdd 12(6): 658-663
Draelos, Z.D. 2006: The effect of a daily facial cleanser for normal to oily skin on the skin barrier of subjects with acne Cutis 78(1 Suppl): 34-40
Makino, E.T.T.; Mehta, R.C.C.; Banga, A.; Jain, P.; Sigler, M.L.L.; Sonti, S. 2013: Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation Journal of Drugs in Dermatology: Jdd 12(3): S16-S20
Wheeland, R.G.; Dhawan, S. 2011: Evaluation of self-treatment of mild-to-moderate facial acne with a blue light treatment system Journal of Drugs in Dermatology: Jdd 10(6): 596-602
Fabi, S.G.; Goldman, M.P. 2013: Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging Journal of Drugs in Dermatology: Jdd 12(3): S32-S37
Péronnet, F.; Adopo, E.; Massicotte, D.; Hillaire-Marcel, C.; Brisson, G.R. 1992: Oxidation rate of four types of carbohydrates ingested 30 min before a period of prolonged exercise at moderate intensity in healthy male subjects Medicine and Science in Sports and Exercise 24(9): 1066-1068
Moore, A.; Kempers, S.; Murakawa, G.; Weiss, J.; Tauscher, A.; Swinyer, L.; Liu, H.; Leoni, M. 2014: Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study Journal of Drugs in Dermatology: Jdd 13(1): 56-61
Friedman, D.; Kutscher, T.D. 2016: Minimal energy eMatrix treatment combined with elure application for an expedited response in the treatment of hyperpigmentation and overall facial skin rejuvenation: A case report series Journal of Cosmetic and Laser Therapy 18(2): 66-68
Fowler, J.; Jackson, M.; Moore, A.; Jarratt, M.; Jones, T.; Meadows, K.; Steinhoff, M.; Rudisill, D.; Leoni, M. 2013: Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies Journal of Drugs in Dermatology: Jdd 12(6): 650-656